`Patent 7,772,209
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`NEPTUNE GENERICS, LLC,
`APOTEX INC., APOTEX CORP., TEVA PHARMACEUTICALS,
`FRESENIUS KABI USA, LLC, and WOCKHARDT BIO AG
`Petitioners,
`
`v.
`
`ELI LILLY & COMPANY,
`Patent Owner.
`__________________
`
`Case No: IPR2016-002401
`Patent No. 7,772,209
`__________________
`
`PATENT OWNER’S REQUEST FOR ORAL ARGUMENT
`
`
`
`
`
`
`
`
`1 Cases IPR2016-01191, IPR2016-01337, and IPR2016-01343 have been joined
`
`with the instant proceeding.
`
`
`
`Case IPR 2016-00240
`Patent 7,772,209
`Pursuant to 37 C.F.R. § 42.70(a) and the Notice of Stipulation Concerning
`
`Scheduling filed on January 23, 2017, Paper 53, Patent Owner Eli Lilly &
`
`Company (“Lilly”) respectfully requests that the Board hear oral argument on all
`
`instituted grounds of unpatentability in this proceeding. Lilly requests that the
`
`Board hear combined oral argument in IPRs 2016-00237, -00240, and -00318
`
`simultaneously. Lilly further requests that one hour of total argument time per side
`
`be allotted. That is, Lilly proposes that Neptune and Sandoz be granted a total of
`
`one hour to present argument, to be divided between them as they choose, and
`
`Lilly be allotted one hour to address Neptune’s and Sandoz’s arguments.
`
`Proceeding in this manner is justified because these proceedings involve the same
`
`patent and the issues in these proceedings, as the briefing has progressed, have
`
`become substantially similar to one another. For example, Lilly’s concurrently-
`
`filed sur-reply is identical in all three proceedings. Lilly respectfully submits that
`
`conducting separate oral arguments between Neptune and Lilly and then Sandoz
`
`and Lilly, as we understand Petitioners will suggest, will be unnecessarily
`
`duplicative and inefficient given the significant similarities in Neptune and
`
`Sandoz’s positions.
`
`Lilly respectfully requests that the Board provide audio/visual equipment to
`
`display demonstrative exhibits and evidence of record from a laptop, including a
`
`projector and screen for displaying documents. Given the number of parties
`
`
`
`2
`
`
`
`Case IPR 2016-00240
`Patent 7,772,209
`involved, Lilly further requests that the Board assign this hearing to Hearing Room
`
`A.
`
`
`
`Date: February 14, 2017
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/David M. Krinsky/
`David M. Krinsky
`Reg. No. 72,339
`Back-up Counsel for
`Patent Owner
`
`Williams & Connolly LLP
`725 Twelfth Street, N.W.
`Washington, D.C. 20005
`202-434-5338 (Telephone)
`202-434-5029 (Facsimile)
`dkrinsky@wc.com
`
`
`
`3
`
`
`
`Case IPR 2016-00240
`Patent 7,772,209
`
`CERTIFICATE OF SERVICE
`(37 C.F.R. § 42.6(e))
`
`The undersigned hereby certifies that the foregoing document was served on
`
`
`
`February 14, 2017 by delivering a copy via electronic mail on the following
`
`attorneys of record for the Petitioners:
`
`Sarah E. Spires
`Reg. No. 61,501
`240Neptune@skiermontderby.com
`
`Skiermont Derby LLP
`2200 Ross Ave., Ste. 4800W
`Dallas, Texas 75201
`P: 214-978-6600/F: 214-978-6601
`
`Attorneys for Neptune Generics, LLC
`
`John D. Polivick
`Reg. No. 57,926
`jpolivick@rmmslegal.com
`
`William A. Rakoczy
`Pro hac vice to be filed
`wrakoczy@rmmslegal.com
`
`Rakoczy Molino Mazzochi Siwik LLP
`6 West Hubbard Street, Suite 500
`Chicago, IL
`P: 312-527-2157/F: 312-527-4205
`
`Attorneys for Apotex Inc. and Apotex
`Corp.
`
`Gary J. Speier
`Reg. No. 45,458
`gspeier@carlsoncaspers.com
`
`
`
`
`Dr. Parvathi Kota
`Reg. No. 65,122
`240Neptune@skiermontderby.com
`
`
`
`
`Deanne M. Mazzochi
`Reg. No. 50,158
`dmazzochi@rmmslegal.com
`
`Patrick C. Kilgore
`Reg. No. 69,131
`pkilgore@rmmslegal.com
`
`
`
`Mark D. Schuman
`Reg. No. 31,197
`mschuman@carlsoncaspers.com
`
`
`
`
`
`
`Case IPR 2016-00240
`Patent 7,772,209
`
`
`
`
`
`
`Bryan P. Collins
`Reg. No. 43,560
`bryan.collins@pillsburylaw.com
`
`
`/David M. Krinsky/
`David M. Krinsky
`Reg. No. 72,339
`Back-up Counsel for Patent
`Owner
`
`
`Date: February 14, 2017
`
`
`
`
`
`Carlson, Caspers, Vandenburgh,
`Lindquist & Schuman
`225 South Sixth Street, Suite 4200
`Minneapolis, MN 55402
`P: 612-436-9600
`F: 612-436-9605
`
`Cynthia Lambert Hardman
`Reg. No. 53,179
`chardman@goodwinprocter.com
`
`Goodwin Procter LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018-1405
`P: 212-813-8800
`F: 212-355-3333
`
`Attorneys for Teva Pharmaceuticals
`USA, Inc. and Kabi Fresenius USA,
`LLC
`
`Patrick A. Doody
`Reg. No. 35,022
`patrick.doody@pillsburylaw.com
`
`Pillsbury Winthrop Shaw Pittman LLP
`1650 Tysons Boulevard
`McLean, VA 22102
`P: 703-770-7755/F: 703-770-7901
`
`Counsel for Wockhardt Bio AG
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`